Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase 2b study of ZEN003694 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer after abiraterone
CTR20211865Phase 2Active
- Sponsor
- Zenith Epigenetics
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ZEN3694, enzalutamide in prostate cancer (PCa), sponsored by Zenith Epigenetics. Started Jul 2022; status: active.
02
Drugs
ZEN3694enzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on CTR20211865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211865.